Abstract：
BACKGROUND: Potential regional differences in cancer incidence and survival would demand targeted interventions to decrease cancer related death.
METHODS: This descriptive cohort study provides an overview of regional cancer incidence and relative survival (RS) in Denmark during 2007-2021. National cancer incidence and RS estimates were calculated similar to the official statistics for the Danish Cancer Registry. Specifically, we estimated age-standardized (World) cancer incidence rates (ASR), and RS in 3-year periods by sex, and the five regions of Denmark (i.e., Region of Northern Denmark, Central Denmark Region, Region of Southern Denmark, Region Zealand, and Capital Region).
RESULTS: We identified 578,107 incident cancers in Denmark during 2007-2021, of which 124 123 were diagnosed in 2019-2021. Small fluctuations were seen in ASR for cancer overall in all five regions during 2007-2018, followed by decreasing trends in 2019-2021. Men exhibited higher ASRs than women. Consistent improvements in 1- and 5-year RS were seen during the study period in all regions. However, for patients diagnosed in 2019-2021, the 5-year RS levelled off. These patients experienced 1-year RS of 83 % among men and 84 % among women, and the 5-year RS was also similar between sexes (men: 67 %, women: 70 %, overall: 68 %). Region Zealand generally presented lower RS estimates for both sexes combined.
CONCLUSIONS: Cancer survival improved between 2007 and 2021 in all Danish regions for both sexes. However, the improvements in cancer survival appeared to have levelled off in the most recent period, 2019-2021. For both sexes, the lowest survival was suggested for Region Zealand.
METHODS: This descriptive cohort study provides an overview of regional cancer incidence and relative survival (RS) in Denmark during 2007-2021. National cancer incidence and RS estimates were calculated similar to the official statistics for the Danish Cancer Registry. Specifically, we estimated age-standardized (World) cancer incidence rates (ASR), and RS in 3-year periods by sex, and the five regions of Denmark (i.e., Region of Northern Denmark, Central Denmark Region, Region of Southern Denmark, Region Zealand, and Capital Region).
RESULTS: We identified 578,107 incident cancers in Denmark during 2007-2021, of which 124 123 were diagnosed in 2019-2021. Small fluctuations were seen in ASR for cancer overall in all five regions during 2007-2018, followed by decreasing trends in 2019-2021. Men exhibited higher ASRs than women. Consistent improvements in 1- and 5-year RS were seen during the study period in all regions. However, for patients diagnosed in 2019-2021, the 5-year RS levelled off. These patients experienced 1-year RS of 83 % among men and 84 % among women, and the 5-year RS was also similar between sexes (men: 67 %, women: 70 %, overall: 68 %). Region Zealand generally presented lower RS estimates for both sexes combined.
CONCLUSIONS: Cancer survival improved between 2007 and 2021 in all Danish regions for both sexes. However, the improvements in cancer survival appeared to have levelled off in the most recent period, 2019-2021. For both sexes, the lowest survival was suggested for Region Zealand.
摘要：
背景：癌症发病率和生存率的潜在区域差异将需要有针对性的干预措施来减少癌症相关的死亡。
方法：这项描述性队列研究提供了2007-2021年丹麦地区癌症发病率和相对生存率（RS）的概述。国家癌症发病率和RS估计值的计算类似于丹麦癌症登记处的官方统计数据。具体来说,我们估计了年龄标准化（世界）癌症发病率（ASR），和RS在3年期间按性别划分，和丹麦的五个地区(即，北丹麦地区,丹麦中部地区,丹麦南部地区,新西兰地区,和首都地区)。
结果：我们在2007-2021年期间在丹麦发现了578,107例癌症，其中124-123在2019-2021年被诊断。在2007-2018年期间，所有五个地区的癌症ASR总体上出现了小幅波动，随后在2019-2021年呈下降趋势。男性表现出高于女性的ASR。在研究期间，所有地区的1年和5年RS均有持续改善。然而,对于2019-2021年诊断的患者，5年RS趋于稳定。这些患者经历了1年RS，男性为83％，女性为84％，男女的5年RS也相似(男性：67%，女性：70%，总体：68%）。新西兰地区总体上对男女两性的RS估计较低。
结论：2007年至2021年，丹麦所有地区男女的癌症生存率都有所提高。然而,癌症生存率的改善在最近一段时间似乎趋于平稳，2019-2021年。对两性来说，建议在新西兰地区存活率最低。
方法：这项描述性队列研究提供了2007-2021年丹麦地区癌症发病率和相对生存率（RS）的概述。国家癌症发病率和RS估计值的计算类似于丹麦癌症登记处的官方统计数据。具体来说,我们估计了年龄标准化（世界）癌症发病率（ASR），和RS在3年期间按性别划分，和丹麦的五个地区(即，北丹麦地区,丹麦中部地区,丹麦南部地区,新西兰地区,和首都地区)。
结果：我们在2007-2021年期间在丹麦发现了578,107例癌症，其中124-123在2019-2021年被诊断。在2007-2018年期间，所有五个地区的癌症ASR总体上出现了小幅波动，随后在2019-2021年呈下降趋势。男性表现出高于女性的ASR。在研究期间，所有地区的1年和5年RS均有持续改善。然而,对于2019-2021年诊断的患者，5年RS趋于稳定。这些患者经历了1年RS，男性为83％，女性为84％，男女的5年RS也相似(男性：67%，女性：70%，总体：68%）。新西兰地区总体上对男女两性的RS估计较低。
结论：2007年至2021年，丹麦所有地区男女的癌症生存率都有所提高。然而,癌症生存率的改善在最近一段时间似乎趋于平稳，2019-2021年。对两性来说，建议在新西兰地区存活率最低。
